Idiopathic retroperitoneal fibrosis: A case report and review of articles

Sanambar Sadeghi 1,*,Mohsen Ayati 1, Mohammad Ali Mohagheghi 1, Shahrirahr Shahriaran 1
Isa Jahanzad 1, Somaye Safavi 1.

ABSTRACT

Idiopathic retroperitoneal fibrosis is a rare disorder of an unknown etiology characterized by an inflammatory proliferative fibrosing process that may involve the ureters in 80-100% of cases. The present study was carried on a 38 years old man who was admitted to Imam Khomeini Hospital with severe abdominal pain and renal failure. Abdominal MRI showed encasement of abdominal aorta and bilateral hydronephrosis. Tissue biopsy established the diagnosis of retroperitoneal fibrosis and ureteral obstruction was managed by insertion of bilateral ureteral stents. Presupposing the un-resectability, medical therapy was started. However he didn’t show objective response to Prednisolone (1mg/kg) and had adverse effects. Subsequently, his disease was controlled by adding mycophenolate mofetil and azathioprine to reduce the steroid dose. After a few months, urinary stents were removed and he had been on complete remission for more than 4 years. Although advanced idiopathic retroperitoneal fibrosis would be effectively treated by a combination of ureteric stents and steroids, in difficult cases, second-line treatment with other immunosuppressive drugs may help to achieve long-term remission of disease.

Keywords: retroperitoneal fibrosis, ureteral obstruction, medical therapy.
**Case Report**

A 38 years old Caucasian man presented with sustained abdominal pain, bloating, nausea and weight loss. There wasn’t any history of change in stool caliber or melena. He had been treated as a case of peptic ulcer over the prior 12 month interval in spite of normal upper GI endoscopy. Colonoscopy examination was normal as well.

On August 2006 the patient referred to emergency room with intractable vomiting due to uremic syndrome. Laboratory examination showed anemia (Hgb=10.5mg/dl), rise of creatinine (5.7) and hyperuricemia (uric acid=13.5). He treated with one occasion of hemodialysis. Results of other investigations were as follows: MCV=82, WBC=7000, platelet=280000, ESR=85, CRP=++++, ANA=negative, urine Banes Jones protein=negative, LDH=476 (upper of normal limit), liver function tests were normal; Iron=20, TIBC=287, reticulocyte=0.3%, calcium=8.7, ALK-PH=171u/l(80-306), and TSH=0.7mu/m(0.4-6). There was non-specific rise of immunoglobulin in serum protein electrophoresis. Serum albumin, amylase, AFP, BHCG, PSA level were normal. Bone marrow aspiration and biopsy showed reactive marrow without any evidence of malignant processes.

Kidney Doppler ultrasonography showed normal renal arteries and veins but bilateral hydronephrosis and nephroscerotic changes. CT-Scan showed evidence of small retroperitoneal adenopathies, multiple opaque-shadows in both ureters and caliceal distention. Consultant urologist placed DJ-catheters in his ureters.

MRI revealed a retroperitoneal mass encasing abdominal aorta, IVC and both ureters extending from infra-renal artery level to aortic bifurcation. The mass was found to be diffusely hypo-intense on T1-weighted imaging and high intense on T2. Small lymph nodes were reported in the level of renal pedicles (Fig 1, 2). Differential diagnosis of the early needle-biopsy under the guide of sonography, he was referred to surgeon for open biopsy.

Laparotomy revealed fixed and ill-defined retroperitoneal mass. Pathology report of biopsied tissue showed fibrous tissue proliferation including broad anastomosing bands of hyalinized collagen infiltrated by numerous in...
Figure 1 – Primary MRI showed periaortic mass and bilateral hydronephrosis, dilatation of proximal part of ureters, stenosis and replacement of medial part of ureters.

Figure 2 – KUB showed replacement of double J – catheters at the level of L3-L4.

Figure 3 – Histopathology few number of myofibroblast.

Figure 4 – Positive staining for IgG4

The patient referred for counseling and management to Cancer Institute on Feb 2007. At the admission he was fit and well-nourished man who complained of sustained abdominal pain that was intractable to analgesic drugs. Medical history revealed he had hypertension and hyperthyroidism in past treated 20 years ago with 131*I. There was no history of abdominal trauma or surgery. He was under therapy with enalapril and levothyroxine. There was no history of betablocker, hydralazine, bromocriptine or ergotamine use. Physical examination was unremarkable except for abdominal distension. Blood pressure and body temperature was 150/90 & 36.7, respectively. Laboratory examination showed Hgb=11.5, BUN=21, Creatinine=1.7, ESR=85, CRP++++, serum IgG was 2100mg/dl (870-1700) and IgG4 was stained in pathology specimen (Fig 4). The high serum IgG concentration and highly positive IgG4 staining of biopsied tissue suggested the possible association with autoimmune pancreatitis. However there was no evidence of pancreatitis on physical or laboratory examinations and imaging.

The patient referred for counseling and management to Cancer Institute on Feb 2007. At the admission he was fit and well-nourished man who complained of sustained abdominal pain that was intractable to analgesic drugs. Medical history revealed he had hypertension and hyperthyroidism in past treated 20 years ago with 131*I. There was no history of abdominal trauma or surgery. He was under therapy with enalapril and levothyroxine. There was no history of betablocker, hydralazine, bromocriptine or ergotamine use. Physical examination was unremarkable except for abdominal distension. Blood pressure and body temperature was 150/90 & 36.7, respectively. Laboratory examination showed Hgb=11.5, BUN=21, Creatinine=1.7, ESR=85, CRP++++, serum IgG was 2100mg/dl (870-1700) and IgG4 was stained in pathology specimen (Fig 4). The high serum IgG concentration and highly positive IgG4 staining of biopsied tissue suggested the possible association with autoimmune pancreatitis. However there was no evidence of pancreatitis on physical or laboratory examinations and imaging.

The patient referred for counseling and management to Cancer Institute on Feb 2007. At the admission he was fit and well-nourished man who complained of sustained abdominal pain that was intractable to analgesic drugs. Medical history revealed he had hypertension and hyperthyroidism in past treated 20 years ago with 131*I. There was no history of abdominal trauma or surgery. He was under therapy with enalapril and levothyroxine. There was no history of betablocker, hydralazine, bromocriptine or ergotamine use. Physical examination was unremarkable except for abdominal distension. Blood pressure and body temperature was 150/90 & 36.7, respectively. Laboratory examination showed Hgb=11.5, BUN=21, Creatinine=1.7, ESR=85, CRP++++, serum IgG was 2100mg/dl (870-1700) and IgG4 was stained in pathology specimen (Fig 4). The high serum IgG concentration and highly positive IgG4 staining of biopsied tissue suggested the possible association with autoimmune pancreatitis. However there was no evidence of pancreatitis on physical or laboratory examinations and imaging.
Patient was treated first with prednisolone 0.5 mg/kg/day. The dose increased to 1 mg/kg after 2 weeks of no response. After six weeks ESR decreased to 50 mm but blood pressure, serum cholesterol and TSH increased. On March 2007 the dose of prednisolone decreased to 0.5 mg/kg/d and cyclosporine 100mg/bid was added to other prescribed drugs including Prednisolone, Omeprazole, Atorvastatin, Aspirin and Levothyroxine. On May 2007 CT-Scan and MRI revealed more than 30% decrease in the size of the mass (Fig 5, 6, 7).

Figure 5 –MRI before treatment: evidence of hydronephrosis, and periaortic mass.

ESR decreased to 10 mm, Hgb raised to 14.2 mg/dl, Cr=0.7, BUN=13, Uric Acid=4.1, CRP-, TSH=2.5. Left and right DJ catheters were removed sequentially. The dose of prednisolone slowly tapered to 5 mg/d in the next six months. Cyclosporine changed to mycophenolate mofetil (CellCept) due to adverse events and few months laterazathiopurine was added to other drugs. On Dec 2010, he was on CellCept 2 mg/daily, azathioprine 50 mg/bid, prednisolone 5 mg/d and levothyroxine 50 mg/d. Furthermore, there wasn’t hydronephrosis or progression of disease on CT scan (Fig 7).

Figure 6 –CT-Scan before treatment: periaortic mass.

Figure 7 –CT Scan after treatment: Almost dissolving of whole retroperitoneal mass. Insignificant residue in anterior of aorta.
The primary description of idiopathic retroperitoneal fibrosis (IRPF) is credited to the French urologist Albaran in 1905. But Ormand completely characterized the disease in 1984. Retroperitoneal fibrosis consists of chronic inflammation and marked fibrosis which often entrap the ureters and other abdominal organs.

There is considerable delay between the onset of symptoms and diagnosis which leads to the late complication of renal failure. Unfortunately our patient experienced the same scenario of longstanding non-specific symptoms leading to bilateral hydronephrosis and renal failure.

The mean age at onset of IRPF is 50-60. Although our patient age was lower and he was suffered from anemia and showed high ESR and CRP suggesting the presence of secondary disease, we couldn’t find related systemic diseases. It should be noted that the above mentioned laboratory findings can arise in both idiopathic and secondary cases.

Although radiation therapy is one of the causes of fibrosis, patient previous history of iodine therapy couldn’t be the cause of his disease due to small dose he received. On the other hand, fibrosis is a local complication in the radiotherapy field and radiation induced fibrosis has mostly sclerotic bases than inflammatory reaction which our patient had.

There is an association between IRPF and autoimmune diseases of thyroid. We haven’t had enough information about the patient previous thyroid problem, might be Graves’ disease or an autonomous nodule in the base of multi-nodular goiter.

Currently there are no standardized criteria for the diagnosis of IRPF. Many physicians make the diagnosis based on clinical symptoms and cross-sectional imaging without biopsy or appropriate histological review. However, several groups have reported that biopsy may actually change the diagnosis in 25% of cases; making interpretation of series without pathology misleading. Biopsy was used for confirmation of imaging findings. We also found aggregate of round mononuclear cells composed of B and T lymphocytes and a plasma cell infiltrate. The plasma cells were IgG-bearing. These cells are involved in the pathogenesis of sclerosing pancreatitis, a disorder that sometimes is associated with IRPF.

Although IRPF is a localized disease, constitutional symptoms and elevated acute-phase-reactants such as ESR and CRP, reduced hemoglobin and elevated gammaglobulin at presentation shows the inflammatory nature of the disease. Thick IgG4 bearing plasmacyte and dense fibrosis that accompanies healing wound appear to be a typical example of Th2-mediated pathology. The importance of mentioned process is good response to glucocorticoids in the early management of IRPF. IRPF responds to corticosteroid initially but recurs without prolonged treatment. More recently, by addition the steroid-sparing agents such as mycophenolate mofetil, cyclophosphamide, and azathioprine or colchicines sustained remission have been attained. Our case is an example of successful long-term medical management of IRPF.

There are different attitudes in management of IRPF. The results of temporary ureteric stenting to relieve obstruction and protect renal function in addition to prescription of oral glucocorticoids and immunosuppressive drugs can alter the course of the inflammatory process. We found what was previously believed to be an uncommon and challenging syndrome, nowadays can be treated successfully with non-surgical approaches.